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Abstract
Nerve growth factor (NGF) has been shown to increase cyclic
AMP in PC12 cells and to potentiate the actions of other
agents that raise cyclic AMP. In our studies, NGF causes over
50% loss of PDE 2 activity (cyclic GMP-stimulated cyclic
nucleotide phosphodiesterase) in PC12 cells within 24 h. After
72 h of NGF treatment, cyclic AMP hydrolysis in PC12
extracts is no longer cyclic GMP-stimulated. NGF deprivation
increases the phosphodiesterase activity of treated cells. NGF
does not decrease either PDE 2 mRNA or immunoreactivity of
PDE 2A2 protein. Incubation of whole cells with micromolar
Na3VO4 mimics NGF treatment, reducing PDE 2 activity in
PC12 cells by over 50% after 24 h, suggesting a phospho-
protein-mediated regulation of PDE 2 activity. Protein kinase
inhibitor effects were dif®cult to assess due to their direct
interaction with the PDE in cell lysates. To study phosphory-
lation in PDE 2 regulation, PDE 2A2 was epitope-tagged, and
stable clonal PC12 cell transfectants were isolated (PC12B
cells). When combined with metabolically labeled 32P-phos-
phoproteins in vivo or in vitro, phosphoproteins of 108, 90, 64,
43, 33 and 19 kDa coprecipitated with epitope-tagged PDE
2A2 in an NGF sensitive manner. A 23-kDa phosphoprotein
containing immunoreactive phosphoserine associated with the
complex in an NGF independent manner. Phosphothreonine
plus phosphotyrosine immunoreactivity at 23, 24, and 64 kDa
as well as the phosphotyrosine immunoreactivity at 108, 90,
64, 43, 33, and 19 kDa required NGF or orthovanadate
treatment. These proteins are hypothesized to be part of an
NGF-regulated complex controlling PDE 2A2 activity.
Keywords: 3 0,5 0-cyclic nucleotide phosphodiesterase, cyclic
AMP, cyclic GMP, nerve growth factor, PC12 cells, PDE 2,
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PC12 cells differentiate into a sympathetic neuronal
phenotype with either nerve growth factor (NGF) or cyclic
AMP treatment (Greene and Tischler 1976; Gunning et al.
1981; Heideman et al. 1985). NGF only slightly increases
cyclic AMP but greatly potentiates the action of agents that
normally raise cyclic AMP in these cells (Baizer and Weiner
1985; Knipper et al. 1993). The activation of the cyclic
AMP response element binding protein (CREB) through
cyclic AMP-dependent protein kinase (PKA) is necessary
for differentiation and can occur by either cyclic nucleotide
phosphodiesterase (EC 3.1.4.17) inhibition, adenylyl cyclase
activation, or the NGF activation of the mitogen-activated
protein kinase (MAPK) pathway (Grewal et al. 1999).
Cyclic AMP stimulates the low molecular weight GTPase
Rap1, which along with PKA is required for the long-term
stimulation of the MAPK pathway caused by NGF (Yao
et al. 1998; York et al. 1998). The cyclic AMP stimulation
of Rap1 uses at least two mechanisms. Cyclic AMP
activates the cyclic AMP-binding GTPase exchange factor
acting on Rap1 and causes the phosphorylation of Rap1 by
PKA (de Rooij et al. 1998; Kawasaki et al. 1998). The
cellular mechanisms by which neurotrophin receptors
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modulate cyclic AMP are unknown. PKA, in conjunction
with other protein kinase pathways also stimulated by NGF,
increases the transcription of genes in PC12 and other
neuronal cells by the activation of the cyclic AMP response
element binding transcription factor, CREB (Riccio et al.
1999; Kaplan and Miller 2000).
PDE 2 is a major cyclic GMP-stimulated cyclic nucleo-
tide phosphodiesterase (E.C. 3.1.4.17) of neuronal tissues
and the PC12 cell (Sonnenburg et al. 1991; Repaske et al.
1993; Sadhu et al. 1999). PDE 2 hydrolyzes cyclic AMP and
cyclic GMP with similar Vmax, but the enzyme from PC12
cells has a lower Km for cyclic GMP than cyclic AMP
(Whalin et al. 1991). When the enzyme is allosterically
stimulated by cyclic GMP binding, its apparent Km for
cyclic AMP is reduced by about four-fold. PDE 2 has
two cyclic GMP binding sites per dimer with an apparent Kd
for cyclic GMP binding of 0.2 mm at the high af®nity site
(Stroop and Beavo 1991). PDE 2 has extensive structural
homology with two other cyclic GMP binding PDEs, PDE 5
(in smooth muscle) and PDE 6 (in photoreceptors)
(Charbonneau et al. 1990). Unlike related cyclic GMP
binding phosphodiesterases, no modulatory proteins
copurify from cyclic GMP af®nity resins with the particu-
late, detergent soluble, PDE 2A2 (Whalin et al. 1988;
Murashima et al. 1990). Cyclic GMP stimulates cyclic AMP
hydrolysis by PDE 2 by binding to an allosteric noncatalytic
cyclic nucleotide binding domain on PDE 2 similar to those
on PDEs 5 and 6 (Soderling and Beavo 2000).
A cyclic AMP requirement for the differentiation of PC12
cells in response to neurotrophin raised the possibility that
cyclic AMP metabolism might be regulated by NGF. The
effects of NGF on cyclic AMP hydrolysis in the presence
and absence of cyclic GMP were examined. PDE 2 protein
and transcript were measured by western and northern
analyses to ensure no loss of PDE 2 protein occured. Since
receptor tyrosine kinases like the NGF receptor modulate a
variety of protein phosphorylation events, potential phos-
phoprotein interactions were identi®ed. We demonstrate
here for the ®rst time that NGF modulates PDE 2 cyclic
nucleotide hydrolysis possibly through regulation of the
phosphoproteins interacting with PDE 2. We suggest NGF
activates a `switch' to make neuronal cyclic nucleotide
metabolism less cyclic GMP sensitive so both nucleotides
stimulate neuronal gene transcription.
Experimental procedures
Culture of PC-12 cells
PC12 cells were cultured with or without treatment with 100 ng
NGF/mL as described (Greene and Tischler 1976). Cells were
plated on 100-mm plates that had been precoated with 50 mg rat
tail collagen and 25 mg poly-d-lysine. After 24 h in this media,
cells were serum deprived for 24 h before initiating all experi-
ments. They were serum-deprived in Optimem (Life Technologies,
Gaithersburg, MD, USA) for 24 h prior to NGF, isobutyl methyl
xanthine (IBMX), or sodium orthovanadate treatment in the same
media. Untreated cells were maintained in serum-free medium for
at least 24 h and in some cases as long as 144 h with no detectable
effect on PDE activity (data not shown). All control cultures
responded to incubation with 100 ng NGF/mL for 24 h with at least
60% of the cells producing neurites. When incubated with NGF for
sustained periods of time, fresh NGF was added every 48 h. NGF
and all cell culture products were obtained from Life Technologies
(Gaithersburg, MD, USA) or Alomon Laboratories (Jerusalem,
Israel) unless noted otherwise. The bicinchoninic acid assay
reagents were obtained from Pierce (Rockford, IL, USA). All
other chemicals were obtained from Calbiochem (La Jolla, CA,
USA), Fisher Scienti®c (Pittsburgh, PA, USA), or Sigma (St Louis,
MO, USA) unless noted otherwise.
Preparation and analysis of RNA
Total RNA was prepared using TriazolTM reagent (Life Technol-
ogies) according to the manufacturer's instructions. Samples were
electrophoresed, blotted for northern analysis and hybridized
according to methods previously described (Bentley et al. 1992).
To produce PDE 2 mRNA probes, PC12 cell PDE 2A cDNAs
were isolated by the polymerase chain reaction (PCR). PC12 cells
were treated for 9 days with 100 ng NGF/mL. Total RNA was
extracted and processed for poly-A selection and random hexamer-
primed ®rst strand cDNA synthesis as described (Bentley et al.
1992). A domain of PDE 2A was ampli®ed using a sense
oligonucleotide corresponding exactly to bases # 1181±1200
(GenBank accession #U21101) of rat PDE 2A (Yang et al.
1994): 5 0-AGGCTCTTCTCCAAGTGGC. The PDE 2A antisense
oligonucleotide corresponds to bases # 2088±2106 of rat PDE 2A:
5 0-CCTCTGTGGTCCAGGTCG. This oligonucleotide pair is
predicted to amplify a PCR product of 925 bases encoding PDE
2A2 residues 383±689. The cDNA produced overlaps codons
conserved in both the allosteric cyclic GMP-binding domain and
the catalytic domain. The PC12 PDE 2A2 is identical to the
described rat brain PDE 2A2 sequence. PCR-derived cDNAs were
extracted from low melting point agarose by direct freeze-crush and
subcloned into the pAMP-1 (Life Technologies), the pCR 3.1
vectors (Invitrogen, Carlsbad, CA, USA), or the pGEM T vectors
(Promega, Madison, WI, USA). Plasmids were sequenced using
dideoxy nucleotide terminators with Sequenase, or in automated
sequencing reactions using Taq polymerase (Wilson et al. 1990;
Bentley et al. 1992). The cDNAs were used as templates for
random priming reactions using [a-32P]dATP and hybridized to
total RNA in northern analysis (Bentley et al. 1992).
CDNA cloning of a PC12 cell PDE 2A
About 1  106 plaques from an undifferentiated PC12 cell lZAPII
cDNA library (Boulter and Gardner 1989) were screened with a
PCR product (pAMP 2 A:383±689). Twenty-two positives were
obtained. The largest was pSK-5.19 A, encoding the open
reading frame of rat PDE 2A beginning at base 1 810 of the
open reading frame (ORF) through the termination codon and 198
bases of 3 0 untranslated sequence (see Fig. 1). Another clone used
to assemble a full-length contiguous PDE 2A ORF was designated
pSK1.22.N (bases 1 350 to 1 1842). Sequencing throughout these
clones veri®ed a single PDE 2 isoform identical to that of rat brain,
PDE 2A2.
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Assessment of neurite formation
Using described criteria (Greene et al. 1987), neurites were
considered cellular processes greater than a cell body diameter
long through the geometric center of the cell. Four ®elds of . 100
adherent cells were inspected for neurites, which were not counted
when greater than three cells clustered together. The per cent cells
with neuritic processes were averaged to give a single value per
plate.
Phosphodiesterase assay
After aspiration of the culture medium, a 100-mm plate was washed
once with 10 mL of phosphate-buffered saline (137 mm NaCl,
10 mm Na2HPO4, 1 mm KH2PO4, 2.7 mm KCl, pH 7.4) at 218C.
The saline was immediately aspirated. Adherent cells were
incubated for 30 min at 2±48C in 20 mm imidazole acetate,
20 mm benzamidine HCl, 20 mm NaF, 2.5 mm EDTA, pH 6.5 and
harvested with scraping at 2±48C. All homogenates were kept at or
below this temperature until assay. Some experiments also used 1%
polyoxyethylene 9 lauryl ether (Lubrol12A9; Sigma) as a detergent.
Cells were disrupted on ice by three bursts of 10 s each from the
maximum intensity setting of a Bransom Ultrasonics (Danbury, CT,
USA). Protein concentrations were determined by the bicinchoninic
acid method (Smith et al. 1985). The remainder of the material was
adjusted to 25% sucrose and aliquoted for storage at 2 708C until
assayed. PDE isoenzyme activities were determined by described
methods using 20 mm MgCl2 with no more than 0.5 mm EDTA and
[3H]cyclic AMP or [3H]cyclic GMP as the substrate (Sonnenburg
et al. 1991). All `unstimulated' and `cyclic GMP-stimulated' assays
were measured in the presence of 2 mm EGTA and no added
calcium to avoid PDE 1 stimulation. All `cyclic GMP-stimulated'
assays contain 2 mm added cyclic GMP with [3H]cyclic AMP as
the substrate at a ®nal 1 mm total cyclic AMP. All points
shown represent product formation linear with protein and time
of assay. Statistical signi®cance of sample differences given
standard errors of the mean for at least three independent
samples performed in triplicate was determined using Student's
t-test.
NGF deprivation
Cells were plated at a density of 1 X105/100 mm dish, and cultured
overnight in 10% fetal calf serum, 5% horse serum. They were
transferred into 5% horse serum medium incubated again over-
night, and treated the next day without or with NGF. After 48 h in
NGF, some plates were washed ®ve times with 10 mL of serum-
free medium and transferred into 10 mL of 5% horse serum alone
as `NGF deprived'.
Sodium dodecyl sulfate±polyacrylamide gel electrophoresis
(SDS±PAGE) and western analysis
SDS±PAGE was performed at high acrylamide : bis-acrylamide
ratio (19 : 0.1) for resolution of both high and low molecular
weight proteins (Hamilton et al. 1993). Samples were made to a
®nal concentration of 1% SDS, 100 mm Tris HCl pH 6.5, 12.5%
sucrose, 5% b-mercaptoethanol, and boiled for 5 min. Samples
were electrophoresed on polyacrylamide gels (12.5% or 14%
acrylamide) and processed for western analysis as described for
antibodies raised against PDE 2A1 (Juilfs et al. 1997). Antibodies
to PDE 1B, PDE 5, phosphoserine, and phosphothreonine were
from Chemicon International, Inc. (Temecula, CA, USA).
Antiphosphotyrosine was from Transduction Labs (Lexington,
KY, USA). Phosphoamino acid antibodies were speci®c by
competition with 100 mm phosphoamino acid (Sigma). Biotinylated
anti FLAG antibody M2 was obtained from Sigma. Unlabeled
FLAG antibody was obtained from Stratagene (La Jolla, CA, USA).
Antirabbit IgG, antibiotin, anti CREB, and antiphosphoserine 133
CREB were obtained from New England Biolabs (Beverly, MA,
USA). Immunoglobulin was stripped from westerns for probing
with multiple antibodies by incubation with agitation in 0.2 N
NaOH, 1% SDS for 10 min at 258C followed by 0.4 m Tris pH 6.5,
5% b-mercaptoethanol, 1% SDS at 708C for 30 min. After washes
in deionized water, the blot was blocked and redeveloped to ensure
no residual antibody was present.
Image analysis and densitometry of autoradiographs and
enhanced chemiluminescent images
A Kodak digital camera was used to capture images of
autoradiographs, which were analyzed directly with Kodak
Digital Science and NIH Image vs. 1.62 software on a Macintosh
platform.
Protein kinase and phosphatase inhibitor treatment of PC12
cells
All homogenizations were carried out in 20 mm NaF. Some
experiments included treatment of intact cells with sodium
orthovanadate for 24 h prior to homogenization, with or without
NGF. These agents were added at the same time and washed
out with PBS as described above. When protein kinase inhibitors
were added with NGF they were introduced 1 h before NGF
treatment.
Fig. 1 PDE 2A cDNA isolated from a PC12 library is identical to the
rat brain isoform. PDE 2 contains an unique amino terminus distin-
guishing the PDE 2A1, 2A2, and 2A3 splice variants, tandem con-
served cyclic GMP binding or GAF sites (cross hatched domains),
and a catalytic domain with residues conserved among PDE gene
families 1±7 and 10±11 (domains in black). PDE 2A2 is unique with
N-terminal sequences that loosely conform with the GAF consensus
sequence. The PCR product initially produced to screen cDNA
libraries and for northern analysis (2 A:383±689) encodes part of
the second cyclic GMP-binding domain and the catalytic domain. A
PC12 cell lZAPII library and PCR overlap mutagenesis were used
to clone 2 A:340±928, full-length PDE 2A2, and an N-terminal
mutant with a FLAG epitope tag and a polyhistidine marker
(FH-PDE 2A2).
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Construction of PDE 2A2 for expression studies and production
of a PC12 cell line with a FLAG-epitope (DYKDDDDK) tagged
PDE 2A2
The epitope tagged PDE was produced to allow precipitation
and af®nity puri®cation of active protein by a commercially
available antibody. The FLAG epitope and a 10-residue histidine
(H10) tag was introduced after the start Met in the following
oligonucleotide encoding the ®rst eight codons of PDE 2A2 with an
additional 5 0 EcoRI site: 5 0-GAATTCAGCATGGACTACAAG-
GACGACGATGACAAGCATCACCATCACCATCACCATCAC-
CATCACGTCCTGGTGTTGCACCACATCC. An identical sense
oligonucleotide encoding the same sequence without the EcoRI site
or the epitope encoding codons, 5 0-AGCATGGTCCTGGTGTTG-
CACCACATCC was also made. An antisense oligonucleotide to
bases 1 717 to 1 738, 5 0-TGTCTCCTGCTGAAGATATCG, was
used with Taq polymerase, PC12 ®rst strand cDNA produced as
described (Bentley et al. 1992), and the sense oligonucleotides
to produce 741 and 795 base cDNAs encoding N-terminal PDE
2A2 (pGEM 2 A:1±246) and FLAG-H10 PDE 2A2 (pGEM
FH-2 A:1±246) chimeric PCR products. These were initially
cloned into the pGEMT vector for sequencing and were used
with the lZAP library clones to construct full-length PDE 2A2
open reading frame cDNAs subcloned into pcDNA 3 (Invitrogen)
for expression.
Construction of the wild-type PDE 2A2 or FH-PDE 2A2
involved splicing pGEM 2 A:1±246 or pGEM FH-2 A:1±246
cDNA from a 5 0 multiple cloning site SstII through the start site and
the epitope tag (for the FH-PDE 2A2) to a BamHI site 1 597 in the
PDE 2A2 sequence into SstII and BamHI cut, lZAPII excised pSK
(2 A:114±616) encoding PDE 2A2 nucleotide sequences from
1 340 to 1 1850. The resulting clone was sequenced from 2 3 to
1 1850, pSK(2 A:1±616). The SstII to NdeI fragment from 2 3 to
1 1684 of PDE 2A2 was cloned into the SstII and NdeI sites of
lZAPII excised cDNA (from 1 560 to 1 2989) designated pSK
(186±928). The ®nal clones produced were designated pSK
(2A2 : 1±928), or pSK(FH-2A2) for the N-terminal epitope tagged
mutant, which were sequenced and identical to PDE 2A2 (outside
the epitope tag for FH-2A2). The FH-2A2 cDNA was subcloned
into pcDNA3 for the generation of stable PC12 cell transfectants.
Transfection of 1  105 PC12 cells in a 100-mm dish was
performed with Lipofectamine (Life Technologies) according to
manufacturers speci®cations. Ten microliters of Lipofectamine was
mixed with 90 mL of serum-free medium in one tube, 10 mg
(10 mL) of pcDNA3 : FH-2A2 was mixed with 90 mL serum-free
medium in a second tube, and the two solutions mixed to form
micelles for 30 min at room temperature. At the end of 30 min,
cells were washed twice with 10 mL serum free medium. Then
800 mL serum-free medium was added to the pcDNA3 : FH-2A2
mixture, which was pipetted on the cells. Cells were incubated for
5 h at 378C and 5% CO2. At this time 10 mL of complete medium
(with 5% heat inactivated horse serum and 10% fetal calf serum)
was added to the cells, which were further incubated 18 h at 378C.
Next, the medium was made 400 mg G418/mL. After one week,
changing the media daily, greater than 99.9% of the cells became
nonadherent and were removed. The G418 concentration was
lowered to 200 mg/mL, for isolation of resistant clones. Over the
next 2 weeks, eight distinct colonies formed on the plate. Colonies
were isolated using cloning rings, trypsinized off the plate, and
replated in 30 mm wells. Established cultures were split into 12
aliquots each and diluted serially on 96-well plates to a dilution
where only one of the 12 subclones grew. This clone was isolated
for further characterization. The clone giving the highest cyclic
GMP PDE activity above untransfected cells (about 2 fold) was
chosen for further use (PC12B).
Production of a 60-kDa recombinant PDE 2A fusion protein
probe
Using a Hind III site at base 1 1018 on the PDE 2A2 open reading
frame and a 3 0 Not I site on the multiple cloning site of the
Bluescript II vector, a cDNA fragment from clone pSK5.19 A
encoding from 1 1018 through the termination codon was inserted
into pET 28b (Calbiochem-Novagen, Madison, WI, USA) to
Fig. 2 NGF lowers cyclic GMP-stimulated
cyclic AMP hydrolysis under conditions
where neurite formation is observed. PC12
cells were grown without (a) or with 100 ng
NGF/mL (b) or 0.1 mM isobutyl methyl
xanthine (IBMX) for 24 h (c). In (d), the per-
centage of cells in each treatment with
neurites are indicated with the standard
error of the mean (SEM) for N  3. In (e),
washed cells were harvested in imidazole
buffer containing 1% Lubrol12A9, NaF, and
protease inhibitors. Total homogenates
were assayed with [3H] cyclic AMP for
phosphodiesterase activity at 1 mM cyclic
AMP in the absence (open bar) or the pre-
sence (closed bar) of 2 mM cyclic GMP. A
unit is given 1 pmol cyclic AMP hydrolyzed/
min/mg protein. SEMs are shown for N  3.
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produce pET PDE 2A: 340±928. This cDNA used the pET vector
start site to produce the His6, T7 epitope-tagged PDE 2A: 340±928
probe.
Interaction with PDE 2A fusion proteins and
immunoprecipitation with anti T7 epitope conjugated agarose
or direct precipitation with anti FLAG agarose
The T7 2 A:340±928 fusion protein was puri®ed by chromato-
graphy on Ni-nitrilotriacetic acid agarose (Qiagen, Chatsworth,
CA, USA). The protocols varied from the manufacturer's in that
extraction buffers used 0.2 m NaCl, 20 mm Tris HCl, 20 mm
imidazole pH 7.5, 20 mm benzamidine HCl, 2  complete
protease cocktail (Roche Molecular Biological, Indianapolis, IN,
USA), 1% Triton X-100 and 1% Lubrol12A9. The fusion protein
eluted at 100 mm imidazoleHCl pH 7.0. Bacterial recombinant
fusion protein required Triton X-100 (0.5% (v/v) or greater) to
remain soluble on freeze±thawing.
For precipitations, total cell homogenates were prepared and
centrifuged at 10 000 g for 30 min at 48C. The supernatant ¯uid
was removed, precleared by incubation of 100±500 mg protein
with 20 mL of a 50% (w/v) suspension of anti T7 epitope
conjugated agarose (Calbiochem-Novagen, for T7 precipitation)
and protein A agarose (Sigma) for 5 min at 48C followed by a
5-min centrifugation at 10 000 g to obtain the precleared super-
natant ¯uid (Studier et al. 1990). Between 1 and 5 mg of T7 2 A:
340±928 was precleared by interaction with 20 mL of a 50% (w/v)
suspension of G-50 sepharose. For precipitation of proteins binding
T7 2 A:340±928, 100±500 mg of PC12 soluble protein was
incubated with 1±5 mg of a puri®ed T7 2 A:340±928 fusion
protein prepared by standard protocols (Hall et al. 1999). The ®nal
reaction mixtures contained 12.5% sucrose, 100 mm NaCl, 0.1%
(w/v) bovine serum albumin (BSA), 1% (v/v) Lubrol12A9, 0.5%
(v/v) Triton X-100, 20 mL 50% (w/v) suspension anti T7 epitope
conjugated agarose, 0.05 m imidazole pH 7.0, 20 mm benzamidine
HCl, 10 mm NaF, and 1.25 mm EDTA. Anti FLAG M2 antibody
(Stratagene) precipitations were similar but performed with 10 mg
antibody and 40 mL protein A agarose or 10 mL M2-agarose.
Speci®c binding to the antibody conjugates occured for 1 h at 48C
on a tumbling mixer. The samples were sedimented at 5000 g for
5 min, washed three times with saline supplemented with 1% (v/v)
Lubrol12A9, 20 mm imidazole, 20 mm NaF, 20 mm benzamidine,
and 2.5 mm EDTA. The pellet was ®nally processed for
SDS±PAGE and autoradiography or western analysis.
FLAG epitopes were visualized with the use of biotinylated
anti FLAG M2 monoclonal antibody (Sigma). Use of biotinylated
anti FLAG M2 required the use of 5% bovine serum albumin as a
blocking agent; all other primary antibodies used 5% non fat dry
milk as a blocking agent. Ten micrograms of a biotinylated anti
FLAG M2 monoclonal is used with about 100 mm2 of membrane.
Anti FLAG immunoreactivity was visualized using a secondary
incubation with either a 1/1000 dilution of streptavidin-conjugated
horseradish peroxidase (Amersham-Pharmacia, Piscataway, NJ, USA)
or antibiotin (New England Biolabs, Inc., Beverly, MA, USA) and
an extended duration chemilumenescent substrate from Pierce.
Radiolabeling of PC12 ATP pools with [32P]
PC12 cells were plated onto collagen and poly-d-lysine as
discussed above at a density of 105 cells/100 mm plate. After
24 h cells were transferred into phosphate-free RPMI 1640 media
(Life Technologies) supplemented with 0.5 mCi H3[
32P]O4. Cells
were incubated 24 h before the addition of NGF. After the
indicated length of time, cells were homogenized and stored at
2 708C until processed for immunoprecipitation experiments.
Results
PDE 2A2 is a cyclic GMP stimulated cyclic AMP
phosphodiesterase activity of PC12 cells
The only known cyclic GMP-stimulated cyclic AMP
phosphodiesterase is PDE 2, which is enriched in PC12
cells (Whalin et al. 1991; Soderling and Beavo 2000). Since
cyclic nucleotides are crucial to the NGF response, probes
were developed by RT-PCR for cDNA encoding PDE 2
(Fig. 1). The initial cDNA product was designated
2 A:383±689, since it encoded these amino acids of rat
PDE 2A2. A full-length PC12 cell derived PDE 2A2
identical in sequence to the previously described PDE 2A2
from rat brain was assembled (Yang et al. 1994). This
protein has an estimated molecular weight of 104 792 Da
and has the conserved C-terminal PDE catalytic domain
from amino acids 641±810 (Soderling and Beavo 2000).
Amino terminal to this is a highly conserved (consensus
E-value 1.2  10237) cyclic GMP binding GAF domain
from amino acids 397±546 (Schultz et al. 2000). Amino
terminal to this GAF domain is a second highly conserved
(E-value 4.2  10222) cyclic GMP binding domain from
amino acids (228±375). Of all the PDE 2 splice variants,
PDE 2A2 is unique in possessing a third GAF-like domain
of loose consensus (E-value 0.54) from amino acids 50±189.
NGF decreases PC12 phosphodiesterase activity under
conditions where neurites are formed
The phosphodiesterase inhibitor IBMX, like NGF, induces
neurite formation with activation of some of the same
pathways involved with cellular differentiation (Figs 2a±d)
(Grewal et al. 1999). Either NGF (100 ng/mL) or IBMX
(100 mm) treatment lowered PC12 cell cyclic nucleotide
phosphodiesterase activity (Fig. 2e). It was found that
NGF-treated cells had lost about half of their cyclic GMP-
stimulated phosphodiesterase activity compared to control
undifferentiated cells (Fig. 2e).
PDE 2 activity rises on NGF deprivation of PC12 cells
A PDE 2 activity decrease is associated with NGF treatment.
A CREB-mediated transcription is an essential part of the
NGF response. Therefore, PDE 2 activity might be expected
to return to normal under conditions of NGF deprivation
where CREB dephosphorylation normally occurs (Riccio
et al. 1999) if PDE 2 regulation was coupled to CREB
dephosphorylation. When cells are treated with NGF for
48 h, washed extensively with serum-free medium, and
subsequently NGF deprived for 24 h, the cyclic GMP
stimulated cyclic AMP hydrolysis is elevated compared to
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48 h or 72 h NGF (Fig. 3). Activity does not fully return to
the level seen in untreated cells. When CREB is immuno-
precipitated from these soluble extracts, processed for
western analysis, and probed with an antibody raised against
the phosphoserine 133 CREB peptide, 48 and 72 h of NGF
treatment are associated with an increase of phosphoCREB
immunoreactivity at about 43 kDa. When cells are washed
and then NGF- and fetal calf serum deprived for 24 h after
48 h of NGF treatment the amount of immunoreactive
phosphoCREB is greatly decreased as is neurite formation.
PDE 2 activity reciprocates with CREB phosphorylation and
the production of neurites in PC12 cells.
NGF decreases PDE 2 activity at concentrations of NGF
producing neurites
The initial loss in activity occurs relatively rapidly (within
24 h) but a slower loss in activity occurs with time (through
120 h). Treatment with 100 ng NGF/mL for 24 h was found
to decrease the cyclic GMP-stimulated cyclic AMP PDE
activity in PC12 cell homogenates by about 50% (Fig. 4a;
N  9 for untreated and 24 h points). Cyclic GMP-
stimulated cyclic AMP phosphodiesterase activity values
obtained from NGF-treated cells differ at a signi®cance
level of p , 0.001 when compared to undifferentiated cell
activities at times greater than or equal to 48 h of NGF
treatment (N  6). With increasing duration of NGF
treatment 75±80% of untreated cell cyclic GMP stimulated
activity was lost, and after 72 h of NGF the cyclic GMP
stimulated activity is not signi®cantly greater than cyclic
AMP hydrolysis alone.
We determined whether PDE 2 was the major cyclic
GMP-hydrolyzing enzyme of the PC12 cell by examining
the sensitivity of the activity to erythro-9-(2-hydroxy-3-
nonyl)-adenine (EHNA), a PDE 2 selective inhibitor with an
IC50 of 10 mm (Podzuweit et al. 1995). The PDE 1, 5 and 6
selective inhibitor zaprinast was examined for its ability to
inhibit PC12 cyclic GMP phosphodiesterase, and zaprinast
had an IC50 of 18 mm (N  4) (Yan et al. 1996). It was
found that EHNA most potently (IC50  9 mm) inhibited
both cyclic GMP stimulated cyclic AMP and cyclic GMP
phosphodiesterase, characteristic of PDE 2A. On fractiona-
tion, cyclic GMP stimulated cyclic AMP and cyclic GMP
phosphodiesterases eluted from DE-52 at 200 mm NaCl
(data not shown). No activity eluting from DE 52 was
calcium plus calmodulin stimulated, nor was PDE 1 activity
found in whole cell homogenates.
The concentration dependence of NGF on cyclic GMP
phosphodiesterase was assessed (Fig. 4b). Concentrations
Fig. 3 NGF deprivation increases PDE 2 activity with CREB depho-
sphorylation and neurite loss. PC12 cells were either untreated (unt
72 h) for the 72 h course of the experiment, exposed to NGF for
48 h (NGF 48 h), 72 h (NGF 72 h), or exposed to NGF for 48 h and
serum deprived further for 24 h (dep NGF 24 h). For panel (a), the
percentage of cells with neurites under these conditions are
assessed and compared to the amount of immunoprecipitable CREB
under each of the four conditions. For panel (b), the difference
between cyclic GMP stimulated cyclic AMP hydrolysis minus unsti-
mulated cyclic AMP hydrolysis is shown. Panel (c) contains western
blot panels showing the amount of immunoreactive CREB and
immunoreactive phosphoserine 133 in the same CREB immunopre-
cipitates.
Fig. 4 NGF decreases PDE 2 activity at concentrations associated
with neurite production. PC12 cells were either untreated or exposed
to 100 ng NGF/mL for 24, 48, 72, 96, or 120 h, washed, homoge-
nized without detergent, and processed for cyclic GMP-stimulated
cyclic AMP phosphodiesterase. Shown are the SEM for N  6. In (a),
open circles (W) indicate cyclic AMP phosphodiesterase alone;
closed circles (X) indicate the hydrolysis of 1 mM [3H]cyclic AMP in
the presence of 2 mM cyclic GMP. In (b), PC12 cells were main-
tained untreated or treated with 0.1, 1, 10, 100, or 1 mg of NGF/mL
for 24 h, washed and homogenized and processed for cyclic GMP
phosphodiesterase assay. Open circles (W) indicate cyclic GMP
phosphodiesterase as indicated by the hydrolysis of 1 mM [3H]cyclic
GMP. SEMs are shown for N  3. 1 unit in (a) or (b) is given 1 pmol
cyclic NMP hydrolyzed/min/mg protein.
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of NGF yielding a half-maximal activity of PC12
cyclic GMP phosphodiesterase were similar to those giving
half maximal neurite formation at 24 h, about 10 ng/mL.
Only higher concentrations of NGF (10 ng/mL or greater)
showed a PDE inactivation of statistical signi®cance
(p , 0.001).
NGF does not decrease the amount of PDE 2 mRNA or
protein in PC12 cells within 48 h
One explanation for loss of PDE 2 activity is that NGF
may decrease the amount of cyclic GMP-stimulated
PDE 2. To assess PDE 2A mRNA, oligonucleotides
corresponding to sequences common to the rat and
bovine PDE 2A cDNAs were used to obtain a probe for
the PC12 PDE 2 mRNA by RT-PCR (Bentley et al. 1992).
Upon sequence analysis, this PCR product was found to be
an exact match for the rat PDE 2A coding sequence from
bases #1181±2106 (Fig. 1). Hybridization was evident to a
4.0±4.4 kB PDE 2A band and weaker bands of higher
molecular weight (Fig. 5a). After NGF treatment for 48 h,
densitometric analyses indicate the 4 kB PDE 2 mRNA is
not diminished signi®cantly (Fig. 5a; densitometry not
shown).
The loss of PDE 2 activity is not accompanied by a loss of
PDE 2 immunoreactive material (Fig. 4b). Processing 5 mg
of a PC12 homogenate for western analysis using a
polyclonal monospeci®c antibody raised to puri®ed bovine
PDE 2A1 revealed protein at Mr 105 000, 60 000, and
50 000. This is similar to the major PDE 2A signals
observed in rat adrenal or olfactory epithelium with this
antibody (Juilfs et al. 1997). Lower molecular weight bands
vary in different preparations and likely represent PDE 2
proteolysis. PC12 cell PDE 2A immunoreactivity was not
decreased by NGF, nor was there any signi®cant decrease in
the amount of the peak (on densitometry) or the apparent
molecular weight of the anti PDE 2 immunoreactive
material with NGF treatment (Fig. 4b). In untreated PC12
mRNA northerns, no signals for PDE 1A, 1B, 1C, or PDE 5
were observed, nor were signals found on western
analysis using commercially available antibodies to PDE
1B or PDE 5, nor were calcium-calmodulin stimulated or
cyclic GMP-speci®c activities found on anion exchange
Fig. 5 NGF lowers cyclic GMP-stimulated cyclic AMP hydrolysis
without a decrease in PDE 2A mRNA or protein. In (a), RT-PCR
derived PC12 cell cDNA corresponding to bases 1 1182 to 1 2106
of rat PDE 2A2 (encoding amino acids 383±689) was used to pro-
duce random primed cDNA probes. Probes were hybridized to
10 mg total RNA collected from untreated cells or cells treated with
100 ng NGF/mL for 24 h. For (b), cells treated without or with NGF
for 48 h were processed for western analysis as described in Experi-
mental procedures. Five micrograms of protein was processed using
rabbit antibody to bovine adrenal PDE 2A1. Shown is the expected
size of PDE 2A2, at 105 kDa.
Fig. 6 NGF effects are similar to those of the phosphatase inhibitor
sodium orthovanadate, and these effects on PC12 PDE 2 activity
are not additive. In (a), either untreated cells (column 1 from the left,
none), cells treated with increasing amounts of sodium orthovana-
date expressed as log [VO4], or treated with 100 ng NGF/mL (NGF
control) for 24 h were washed, homogenized, and processed for
cyclic GMP phosphodiesterase activity at 1 mM [3H] cyclic GMP in
the presence of detergent as described above. In comparison,
extracts of untreated cells assayed with 2 mM Na3VO4 directly added
to the assay (assay control) are also shown. SEMs are shown for
N  3 with units equal to pmol cyclic GMP hydrolyzed/min/mg pro-
tein. In (b), after 24 h untreated cells or cells treated with 100 ng
NGF/mL (NGF), 30 mM sodium orthovanadate (VO4), or both
(NGF 1 VO4), were washed, homogenized, and assayed without
detergent for unstimulated (open bar) or cyclic GMP-stimulated
(closed bar) cyclic AMP phosphodiesterase at 1 mM [3H] cyclic AMP.
Shown are SEM for N  4 with units equal to pmol cyclic AMP
hydrolyzed/min/mg protein.
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chromatography from normal or NGF treated cells (data not
shown).
In the absence of changes in PDE mRNA or protein
levels, a potential mechanism for the loss of PDE 2 activity
due to NGF treatment would be a covalent modi®cation of
PDE 2 or a regulatory protein. Homogenization using a non-
speci®c phosphatase inhibitor (NaF) was needed to observe
NGF inhibition of PDE 2 (data not shown). So, intact cells
were treated with a more potent phosphatase inhibitor to
reproduce the NGF effect.
Incubation of intact cells, but not cell extracts, with
phosphatase inhibitors decreases the activity of PDE 2
Sodium orthovanadate is an effective tyrosine phosphatase
inhibitor (Gordon 1991). When PC12 cells are treated for
24 h with 30 mm sodium orthovanadate, cyclic GMP PDE
activity decreases to a level equivalent to 24 h incubation
with NGF (Fig. 6a). Orthovanadate (up to 1 mm) caused
over 90% inhibition of cyclic GMP PDE in adherent
cells. Addition of 2 mm orthovanadate to untreated cell
homogenates has no effect on PDE 2 activity (Fig. 6a). At
100 ng/mL NGF, 30 mm orthovanadate does not further
surpress PDE 2 activity (Fig. 6b). Since orthovanadate
lowered PDE 2 only during incubation with intact cells, a
regulatory mechanism involving protein phosphorylation
was suggested.
Tyrosine kinase and protein kinase C inhibitors have been
used to demonstrate protein kinase pathways, but these
compounds directly inhibit and activate phosphodiesterases
depending on the isozyme and the inhibitor concentration
(Eckly Michel et al. 1997; Nichols and Morimoto 2000). We
found that genistein (100 mm), staurosporine (10 nm),
PD98059 (100 mm), SB203580 (10 mm), and calphostin C
(100 nm) all had direct interactions with the enzyme (data
not shown). PDE-kinase inhibitor interaction dictates a
cautious interpretation of kinase regulation of PDE activity
in vivo.
Under conditions where NGF inhibits PC12 cyclic GMP
PDE, phosphate containing proteins are observed to
interact with recombinant PDE 2 proteins
To assess PDE 2 phosphoprotein regulation by NGF, a
FLAG epitope tagged PDE 2A2 mutant was constructed
under the control of a CMV promoter in a G418 resistance
vector (FH-PDE 2A2, Fig. 1) and transfected into PC12
cells. One clonal cell line was obtained by limiting dilution
of a G418 resistant colony and designated PC12B. This
clonal cell line had twice the speci®c activity of cyclic
GMP phosphodiesterase of PC12 cells and 50% of the
cyclic GMP phosphodiesterase immunoprecipitated with
anti FLAG M2 antibody (data not shown). PDE activity was
lowered by 0.1% SDS, so a washing protocol using 1%
Lubrol12A9 and 0.1% Tween was developed to preserve
PDE 2 activity. Under these conditions, control PC12
cell PDE 2 activity was not precipitated (Fig. 7a) while
PC12B PDE 2 activity and immunoreactivity could be
observed. NGF treated PC12B cells had less immunopreci-
pitated cyclic GMP stimulated cyclic AMP PDE activity
without loss of FLAG immunoreactivity on western
Fig. 7 NGF treatment causes an increase in the 32P content of
proteins associating with PDE 2. In (a), PC12 cells or PC12B cells
(stable FH-PDE 2A2 transfectants) were serum deprived for 24 h,
and the cells were subsequently exposed to 100 ng NGF/mL for
48 h. The detergent-extracted precleared supernatant ¯uid, 100 mg
of cell protein, was incubated with 10 mg of anti FLAG M2, sedimen-
ted, washed, and aliquots were processed for SDS±PAGE and
western blotting (top panel) or phosphodiesterase activity (bottom
panel). A band corresponding to the size of PDE 2A2 at 105 kDa is
indicated. For enzyme activity, open bars indicate cyclic AMP hydro-
lysis, black bars indicate cyclic GMP-stimulated cyclic AMP hydro-
lysis, and the units shown are pmol cyclic AMP hydrolyzed/min/mL
cleared soluble fraction. Grey bars indicate cyclic GMP hydrolysis,
and the units shown are pmol cyclic GMP hydrolyzed/min/mL. In (b),
ATP pools of PC12 or PC12B cells were equilibrated with 0.25 mCi
[32P] orthophosphate under conditions of serum deprivation for 24 h,
and the cells were subsequently exposed to 100 ng NGF/mL for
48 h. Cells were lyzed in homogenization buffer with 1% Lubrol
12A9, precleared, and 100 mg of cell protein was interacted with
1 mg of T7 2A2: 340±928 and anti T7 agarose or 10 mg of anti
FLAG M2 and protein A agarose, sedimented, washed, and
processed for SDS±PAGE and autoradiography.
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analysis, or any shift in the apparent molecular weight of the
FLAG immunoreactivity with NGF treatment (Fig. 7A).
Some interaction of the anti FLAG with material migrating
at 60 kDa was evident but unchanged with NGF treatment
(data not shown) suggesting the N-terminal FLAG epitope is
not lost by proteolysis.
To assess the role of protein phosphorylation in PDE 2
regulation, cellular ATP pools were equilibrated with [32P]-
orthophosphate during serum deprivation for 24 h. The cells
were exposed to NGF and lyzed to obtain a detergent
soluble, protein A agarose and anti T7 epitope agarose
precleared fraction. This was precipitated with anti FLAG or
incubated with a T7 epitope tagged recombinant PDE 2
fusion protein isolated from Escherichia coli (T7 2 A:340±
928, Fig. 1) and precipitated with the anti T7 epitope
antibody. An increase in phosphoproteins (108, 90, 64, 43,
33 and 19 kDa) associating with added T7 2A2 : 340±928
was evident after 24 h of incubation with NGF in either cell
line (Fig. 7b). While anti FLAG M2 precipitated none of
these proteins from PC12 controls, the FLAG antibodies
precipitated multiple high molecular weight proteins from
PC12B cells as well as proteins at 108, 90, 64, 43, 33 and
19 kDa in an NGF-dependent manner (compare lanes 3 and
6; Fig. 7b). The lighter precipitation pattern with the protein
added in vitro could be the result of better protein interaction
with a full-length ORF (the T7-tagged PDE lacks the ®rst
340 amino acids found in FH-PDE 2A2), cotranslational
association, or an increased association intracellularly due to
a higher effective concentration of the FH PDE 2 in PC12B
cells.
Similar interacting phosphoproteins associate with recom-
binant PDE whether it is directly added to a cell extract or
expressed in the cell in vivo. The NGF-sensitive increase in
phosphoprotein association with PDE 2 may re¯ect a greater
turnover of phosphate on protein after NGF treatment or the
net increase in the synthesis of proteins able to bind PDE
2A. To examine whether this change in phosphoprotein
association exhibited the same NGF concentration depen-
dence as PDE 2 inactivation, nonradioactive and metaboli-
cally labeled PC12B cells were treated with a range of NGF
Fig. 8 NGF causes a differential increase in phosphoprotein asso-
ciation with PDE 2A where it causes a decrease in cyclic GMP
hydrolysis. In (a), PC12B cells were preloaded with 1 mCi [32P]-
orthophosphate for 24 h with serum deprivation and for 48 h with
the indicated concentration of NGF. A detergent extract was pre-
cleared with protein A agarose, anti T7 agarose, and precipitated
with anti FLAG M2-protein A agarose complexes. The pellet washed
as and processed for SDS±PAGE and autoradiography. Bands
selected for further study by image analysis are indicated by sym-
bols. In (b), the autoradiograph bands shown in (a) at Mr  85 000
(W), 35 000 (X), 23 000 (D), and 19 000 (P;) are photographed in a
digital camera and analyzed for pixel intensity changes in response
to increasing NGF. In (c), cells were treated identically to those
described in (a) except [32P]-ortho-phosphate was omitted. After
being incubated with the indicated amount of NGF for 48 h and pro-
cessed for FLAG immunoprecipitation, aliquots of the precipitate
were processed for anti FLAG western blots (bottom panel) while
other aliquots were assayed for cyclic AMP phosphodiesterase
using [3H] cyclic AMP at 1 mM with 2 mM cyclic GMP (top panel).
Units shown are pmol cyclic AMP hydrolyzed/min/mL extract
assayed.
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concentrations, detergent extracted, and processed for
FLAG immunoprecipitation.
NGF causes an increase in PDE 2 associated
phosphoproteins at concentrations producing a loss of
PDE 2 activity
PC12B cells incubated with concentrations of NGF which
lower PC12 PDE 2 activity had an increased amount of
32P-containing proteins at 108, 90, 64, 43, 33 and 19 kDa
(and others) interacting with FH-PDE 2 expressed in vivo
(Fig. 8a). The 108 kDa protein might represent FH-PDE
2A2, but it is labeled to some extent even in untreated cells
(Fig. 8a). FH-2A2 puri®cation on Ni-NTA agarose followed
by cyclic GMP sepharose adsorption and elution revealed no
radiolabeled bands (data not shown). Digital quantitation of
protein interactions showed that several phosphoproteins
were immunoprecipitated with PDE 2. Some phosphopro-
teins were sensitive to NGF treatment, such as the proteins
at Mr  84 000, 33 000, and 19 000 (Fig. 8b), while others
were insensitive to NGF treatment such as the Mr  23 000
protein. Half maximal effects of NGF, for the NGF sensitive
phosphoproteins, occured at approximately 10 ng NGF/mL.
This same concentration of NGF produced half maximal
inhibition of anti FLAG precipitable FH-PDE 2 activity
(Fig. 8c).
The NGF receptor does not interact with immuno-
precipitable FH-PDE 2 (data not shown), but many of anti
FLAG: FH-PDE 2 precipitable bands contained phosphotyr-
osine as evidenced by antiphosphotyrosine (pTyr) inter-
action (Fig. 9). The differential incorporation of phosphate
is strikingly evident when the same blot is sequentially
probed, developed, completely stripped of the inital
antibodies, and reprobed with another speci®c antibody as
in Fig. 9. NGF or orthovanadate treatment increase the
intensity anti pTyr staining of bands at 19, 24, 33, 43, 64, 83,
and 90 kDa. Some of these proteins, like the 23 kDa band,
also interact with antiphosphoserine (pSer) without chan-
ging on NGF treatment. The antiphosphothreonine (pThr)
and antiphosphotyrosine (pTyr) staining proteins at 24 and
120 kDa are very sensitive to NGF or orthovanadate
treatment of the whole cell. Many of the phosphoproteins
visible on in vivo labeling are poorly resolved on
immunostaining, indicating these bands may be low
abundance proteins. Like PDE 2, the FLAG-tagged PDE
2A2 protein is partially proteolyzed. The anti FLAG
interacts with the some of the same sized proteolytic
products (around 60±65 kDa) as the polyclonal PDE 2
antibody, but their relative intensities vary due to their target
epitopes. The monoclonal raised to the N-terminal FLAG
epitope and the polyclonal rabbit antibody raised to the
whole PDE 2A1 protein would be expected to interact
differentially. These results potentially explain why the
FLAG epitope worked so much better in our hands to
precipitate an NGF-sensitive PDE : the FLAG epitope
provides a `handle' for the antibody to recognize that NGF-
regulated proteins do not compete for in binding to the
phosphodiesterase.
Discussion
NGF treatment of PC12 cells has effects on cyclic
nucleotide metabolism, and PDE 2 is a major cyclic AMP
phosphodiesterase in PC12 cells (Whalin et al. 1991). Some
effects may be mediated by regulation of PDE 2, since NGF
reduces PDE 2 within 24 h by about 50% and to about 80%
on sustained NGF treatment. NGF does not reduce either
PDE 2 mRNA or protein. NGF treatment correlates with an
increased 32-phosphorous content of speci®c proteins that
copurify with the enzyme through immunoprecipitation.
Proteins of the same size interact directly in vitro with added
recombinant PDE 2 as well as in vivo with the epitope
tagged full-length PDE 2A2, although in vivo expressed
Fig. 9 NGF or sodium orthophosphate cause differential increases
in phosphoserine, phosphothreonine, or phosphotyrosine immunor-
eactivity of FH-PDE 2A2 associated proteins. Soluble fractions
(1 mg protein) from either untreated cell (con), cells treated for 24 h
with 100 ng NGF/mL (NGF), or 30 mM sodium orthovanadate (VO4)
were precleared with anti T7 agarose plus protein A agarose, preci-
pitated with anti FLAG M2 agarose, and processed for western ana-
lyses. The blot was probed sequentially with antiphosphoserine
(pSer), antiphosphothreonine (pThr), antiphosphotyrosine (pTyr), anti
FLAG M2 (anti FLAG) and anti PDE 2 (PDE 2) and exposed from 1
to 10 min depending on the antibody. Between different antibodies
the blot was stripped of IgG as described in the Experimental proce-
dures section, washed, and developed again with chemilumenescent
peroxidase substrate to ensure none of the previous conjugate
probe remained.
Phosphoprotein regulation of PC12 PDE 2A 1261
q 2001 International Society for Neurochemistry, Journal of Neurochemistry, 76, 1252±1263
full-length PDE 2 binds PC12 phosphoproteins better than
PDE 2: 340±928 added in vitro. Whether this is due to
additional sequence of the in vivo expressed protein or
cotranslation is unclear at this time.
The PC12 proteins associated with PDE 2 are not likely to
be known subunits of other PDE isoforms. Detergent
solubilized, anion exchange puri®ed PDE 2 from brain
does not elute from cyclic GMP af®nity resins with
detectable levels of bound proteins (Murashima et al.
1990). We found similar results using anion exchange
puri®ed PDE 2 extracts from detergent solubilized PC12
cells (data not shown).
Other PDEs form protein complexes modulating their
activity and localization through protein kinase pathways.
PDE 4 splice variants have regulatory interactions localized
in their unique amino termini. PDE 4D4 and PDE 4A5 bind
to src, lyn, and fyn kinase SH3 domains to alter the
conformation of the PDE catalytic domain as detected by
increased rolipram potency (Houslay and Kolch 2000).
While a PKA phosphorylation has been described for
PDE 2A2 and not PDE 2A1, this phosphorylation has no
effect on enzymatic activity (Whalin et al. 1988). Three
splice variants of a single PDE 2 gene are known (Rosman
et al. 1997). PDE 2A1, 2, and 3 are nearly identical except
for their 25, 37, and 44 residue amino termini. The PDE 2A2
gene product, found largely in the brain, partitions into
particulate and soluble fractions (Whalin et al. 1988;
Murashima et al. 1990; Yang et al. 1994).
NGF has more complex effects on cyclic nucleotide
metabolism than simply on PDE 2. PDE 4 is also a major
PC12 PDE isoenzyme (Chang et al. 1997). NGF-mediated
activation of ERKs would be expected to inhibit some PDE
4 isoforms (Houslay and Kolch 2000).
NGF decreases soluble guanylyl cyclase activity. Cyclase
activity and protein are lowered within 24 h after a rapid
(2±4 h) decrease in soluble guanylyl cyclase a1 and b1
mRNA expression (Liu et al. 1997). NO acts like millimolar
cyclic GMP to increase the ef®cacy of NGF, but also
stimulates PC12 neurite formation independently of cyclic
GMP (Hindley et al. 1997; Phung et al. 1999). NO donors
do not lower PDE 2 or change the ability of NGF to lower
PDE 2 activity (data not shown).
The physiological need for decreasing PDE activity in
response to NGF may be to increase the ef®cacy of agents
which activate adenylyl and guanylyl cyclase, supporting
the activation of other cyclic nucleotide mediated processes,
such as CREB phosphorylation. NGF is hypothesized to
activate a `switch' to make neuronal cyclic nucleotide
metabolism less cyclic GMP sensitive. NGF `primes' the
cell for cyclic AMP regulation through PDE 2 inhibition.
We suggest that the regulation of PDE 2 activity occurs
through association of phosphoproteins with PDE 2 in
response to NGF. The pathway by which phosphorylation
and association of these proteins alters phosphodiesterase
activity in PC12 cells should reveal novel PDE regulatory
mechanisms affecting cyclic nucleotide metabolism.
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